Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Injections, Intradermal Clear all
Completed Phase 1 Interventional

A Phase I/II Study of Delayed-Type Hypersensitivity (DTH) Reactions to Intradermal HIV Envelope Antigen

NCT00000782
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (Immuno-AG), gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
4
States / cities
Palo Alto, California • San Jose, California • San Mateo, California + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 25, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Performance and Safety Evaluation of an Intradermal Delivery Device

NCT01359111
View directory record Official record
Conditions
Injections, Intradermal
Interventions
PATH ID Adapter
Device
Lead sponsor
PATH
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 25, 2026, 7:58 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

XVIE to Treat Androgenetic Alopecia (AGA)

NCT07482423
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Decellularized allogeneic human amniotic fluid, Sodium chloride 0.9% injectable solution
Biological · Drug
Lead sponsor
Restore Biologics Holdings, Inc. dba Xtressé
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Orlando, Florida • Marriottsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 25, 2026, 7:58 AM EDT
Recruiting Phase 4 Interventional

OnabotulinumtoxinA for Trigeminal Neuralgia

NCT06216886
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
OnabotulinumtoxinA 100 UNT [Botox], Sodium Chloride 0.9% for Injection, Preservative Free
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 25, 2026, 7:58 AM EDT
Completed Not applicable Interventional

Two-Stage Tuberculin (PPD) Skin Testing in Individuals With Human Immunodeficiency Virus (HIV) Infection

NCT00000955
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Tuberculin Purified Protein Derivative
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
14
States / cities
New Haven, Connecticut • Wilmington, Delaware • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Oct 25, 2026, 7:58 AM EDT
Completed Not applicable Interventional

Platelet Rich Plasma (PRP) for Vulvar Lichen Sclerosus

NCT03045172
View directory record Official record
Conditions
Lichen Sclerosus of Vulva
Interventions
Platelet Rich Plasma, Placebo
Biological · Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 25, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers

NCT03603431
View directory record Official record
Conditions
Healthy Volunteer
Interventions
MRG-110, Placebo
Drug
Lead sponsor
miRagen Therapeutics, Inc.
Industry
Eligibility
19 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 25, 2026, 7:58 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

HIV Candidate Vaccine, ALVAC-HIV-1, Administration in HIV-Negative Adults

NCT00013572
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
ALVAC-HIV MN120TMG (vCP205)
Biological
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 7:58 AM EDT
Terminated Not applicable Interventional

Intracutaneous Sterile Water Injections for Acute Low Back Pain in the Emergency Department

NCT04240483
View directory record Official record
Conditions
Low Back Pain
Interventions
Intracutaneous sterile water injections (ISWI) group, Intracutaneous dry injections (IDI) group
Other
Lead sponsor
Lindsey schmelzer
Federal
Eligibility
18 Years to 64 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 25, 2026, 7:58 AM EDT
Completed Phase 2 Interventional

Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation

NCT00949754
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
honeybee venom (Apitoxin (Korea) Apitox (USA))
Drug
Lead sponsor
Apimeds, Inc.
Industry
Eligibility
35 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Pinellas Park, Florida • Chicago, Illinois • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2010 · Synced Oct 25, 2026, 7:58 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

NCT06826196
View directory record Official record
Conditions
Alopecia Areata (AA)
Interventions
ALD-102 Solution, Placebo or Control
Drug · Other
Lead sponsor
Aldena Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Thousand Oaks, California • West Lafayette, Indiana • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 25, 2026, 7:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

NCT01011049
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine USP Trivalent Types A and B
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
44
States / cities
Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 25, 2026, 7:58 AM EDT
Completed Phase 1Phase 2 Interventional

A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar

NCT02956317
View directory record Official record
Conditions
Hypertrophic Scar
Interventions
STP705, Placebo
Drug
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 25, 2026, 7:58 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes

NCT06919796
View directory record Official record
Conditions
Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2
Interventions
COMIRNATY®
Biological
Lead sponsor
PharmaJet, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 25, 2026, 7:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Site Selection for Intracutaneous Saline Delivery

NCT01767324
View directory record Official record
Conditions
Intracutaneous Drug Delivery
Interventions
Injection to deltoid, Injection to forearm, Injection to thigh
Device
Lead sponsor
FluGen Inc
Industry
Eligibility
18 Years to 49 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 25, 2026, 7:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Performance and Safety of Two Intradermal Delivery Devices.

NCT01943110
View directory record Official record
Conditions
Injections, Intradermal
Interventions
ID adapter (autodisable), ID adapter (side load)
Device
Lead sponsor
PATH
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 25, 2026, 7:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)

NCT01689363
View directory record Official record
Conditions
Allergic Skin Reaction
Interventions
Hyaluronidase, Histamine, Saline
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
253 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
5
States / cities
Eugene, Oregon • Lake Oswego, Oregon • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 25, 2026, 7:58 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

BTX-A Treatment for Palmar Hyperhidrosis

NCT01262339
View directory record Official record
Conditions
Primary Focal Hyperhidrosis of the Hands
Interventions
BTX-A
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
16 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 25, 2026, 7:58 AM EDT
Completed Phase 1 Interventional

A Phase I/II Dose Escalation Study of Intradermal gp160 to Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses and Immunogenicity in Asymptomatic HIV Seropositive Patients With More Than 400 CD4+ Cells

NCT00000667
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 25, 2026, 7:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study

NCT01737710
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Fluzone® Intradermal Vaccine, Fluzone® (Intramuscular) vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years · Female only
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 25, 2026, 7:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of GENEVAX-HIV, a Possible Vaccine

NCT00002232
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
APL 400-003
Biological
Lead sponsor
Wyeth-Lederle Vaccines
Industry
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 7:58 AM EDT
Completed Phase 2 Interventional Results available

Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis

NCT00928447
View directory record Official record
Conditions
Dermatitis, Allergic Contact
Interventions
rHuPH20, Placebo
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Michigan City, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 25, 2026, 7:58 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids

NCT03601052
View directory record Official record
Conditions
Keloid
Interventions
Remlarsen, Placebo
Drug
Lead sponsor
miRagen Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Aventura, Florida • Chicago, Illinois • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 25, 2026, 7:58 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Intracutaneous Sterile Water Injections

NCT01513447
View directory record Official record
Conditions
Labor Pain
Interventions
Intracutaneous injections
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 2, 2015 · Synced Oct 25, 2026, 7:58 AM EDT